← Human Trials & Peer-Reviewed Studies
A Study of LY3437943 in Participants With Type 2 Diabetes
Plain-language guide to NCT04867785: phase 2 randomized trial of Retatrutide and Dulaglutide, 281 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT04867785
- Phase
- phase 2
- Status
- completed
- Start
- 2021-05-13
- Completion (planned or actual)
- 2022-07-08
- Participants
- 281 (actual)
- Design
- randomized, double-blind, treatment
- Conditions studied
- Type 2 Diabetes
- Results posted
- yes
What This Study Did, in Plain Language
What Was Tested
In this phase 2 trial, researchers set out to test Retatrutide and Dulaglutide.
This study will last about 43 weeks.
The registry classes the interventions as drug.
Who Took Part
281 actual participants took part.
It was open to people of any sex aged from 18 years up to 75 years.
Healthy volunteers were not accepted; participants needed the condition being studied.
Examples of who could join: Have Type 2 Diabetes (T2D).
The full record lists 2 inclusion and 10 exclusion criteria; among the exclusions: have type 1 diabetes mellitus (t1dm); have ketoacidosis; have retinopathy, maculopathy.
How the Study Was Run
Design: randomized, parallel-group and double-blind.
Random assignment meant chance, not the researchers, decided who got Retatrutide and who got the comparison, which limits bias.
The Retatrutide group and the comparison group ran side by side rather than switching.
As a double-blind Retatrutide study, the assignments were hidden from both participants and investigators until the end.
Those kept unaware of assignments: participant and investigator.
It started in 2021-05-13 with completion listed for 2022-07-08.
It ran at 43 sites in United States (40) and Puerto Rico (3).
Its stated primary purpose is treatment.
What Was Measured
Primary outcome: Change From Baseline in Hemoglobin A1c (HbA1c) (time frame: Baseline, 24 Weeks).
It also tracked 9 secondary outcomes, for example Change From Baseline in HbA1c, Change From Baseline in HbA1c, Change From Baseline in Fasting Blood Glucose (FBG), Change From Baseline in Fasting Blood Glucose (FBG), Change From Baseline in Body Weight and Change From Baseline in Body Weight.
What This Means in Plain Language
Put simply, this is a phase 2, randomized trial of Retatrutide and Dulaglutide in 281 people.
The trial is marked completed; results are posted on the registry, and this page does not restate them.
More context: the Retatrutide compound page and the Dulaglutide compound page, all human trials.
Our Notes on the Compounds
Retatrutide: A single-molecule triple agonist (GLP-1, GIP and glucagon receptors).
Dulaglutide: A once-weekly GLP-1 receptor agonist (two GLP-1 analog chains joined to an antibody Fc fragment), sold as Trulicity.
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.